Celcuity completes enrollment for PIK3CA mutant cohort in phase 3 trial

Celcuity Inc. (CELC) has completed enrollment for the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 breast cancer trial, with topline data expected in late Q1 or Q2 2026, building on encouraging Phase 1b results showing a median PFS of 14.6 months. The company also reported positive Phase 1 prostate cancer data, secured a $500 million credit facility, and had its New Drug Application for gedatolisib in advanced breast cancer accepted by the FDA for Real-Time Oncology Review. These advancements, coupled with a 407% stock return over six months and a Guggenheim Buy rating, underscore significant pipeline momentum and growing investor confidence despite the company's current unprofitability.

Analysis

Celcuity Inc. (CELC) has achieved a significant milestone by completing enrollment for the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial, with topline data expected in late Q1 or Q2 2026. This development follows a remarkable 407% stock return over the past six months, indicating strong market confidence. The FDA's acceptance of gedatolisib's New Drug Application for advanced breast cancer under Real-Time Oncology Review further validates the drug's potential and regulatory pathway.

Encouraging Phase 1b trial results for gedatolisib demonstrated a median progression-free survival (PFS) of 14.6 months in the entire PIK3CA mutant patient subgroup, improving to 19.7 months for the intermittent dosing regimen utilized in VIKTORIA-1. Beyond breast cancer, the company reported positive Phase 1 data for gedatolisib in prostate cancer, showing a median radiographic PFS of 9.1 months. This robust pipeline activity, including the ongoing VIKTORIA-2 trial, underscores the broad therapeutic potential of gedatolisib.

Despite current unprofitability, with an EPS of -$3.45 over the last twelve months, Celcuity maintains a strong financial position, supported by a healthy current ratio of 4.58 and moderate debt levels. The recent securing of a $500 million credit facility provides substantial funding for its ongoing drug development efforts. Wall Street analysts have responded positively, with price targets ranging from $60 to $110 and Guggenheim initiating coverage with a Buy rating, citing significant sales potential.

Key Decisions for Investors

• Monitor the upcoming topline data release for the VIKTORIA-1 trial in late Q1 or Q2 2026, as this will be a critical catalyst for future stock performance.
• Evaluate the long-term commercial potential of gedatolisib across its multiple indications, particularly considering the positive early-phase data in prostate cancer and the FDA's Real-Time Oncology Review designation.
• Assess the company's cash burn rate against its $500 million credit facility and strong current ratio, given its pre-profitability stage and significant R&D expenses.